Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Isotechnika -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (86)	7/16/2003 11:06:50 AM
From: Icebrg	Respond to of 285

Immunosuppression and Infection: Opposing Challenges in Solid Organ Transplantation medscape.com This is some background information published by Medscape from the recent transplantation conference. One of the take-home messages is that there appears to be a trend of trying to get away from the use of Cyclosporin. Erik From one of the articles. Conclusion Elimination of calcineurin inhibitors from the transplant immunosuppressive regimen remains a promising approach for those who experience nephrotoxicity and can potentially delay graft failure. Elimination of calcineurin inhibitors after 3 months posttransplantation results in increased short-term acute rejection rates; however, renal function is improved short term with a trend toward better graft success. Withdrawal and avoidance strategies are becoming increasingly relevant and may become practice of care in managing transplant patients.